Focus area
Long QT Syndrome
An inherited or acquired heart rhythm abnormality
Long QT Syndrome (LQTS) is a heart rhythm condition in which the heart takes longer than usual to recharge between beats. This prolongation can increase the risk of potentially serious cardiac arrhythmias.
Understanding LQTS
The heart's electrical rhythm
A prolonged QT interval can dramatically increase the risk of abnormal heart rhythms. Patients may experience fainting or seizures, or may die suddenly. Diagnosis and care should be guided by a healthcare professional.
QT interval
The QT interval on the ECG measures how long the heart takes to electrically recover after each beat
Genetically-driven or acquired
Inherited mutations in different genes delay the heart's electrical recovery and raise the risk of serious arrhythmias
Individual care
Disease management depends on the diagnosis, symptoms and individual risk, in consultation with a specialist.
Acquired Long QT
QT prolongation can also develop through medicines, electrolyte imbalances, environmental factors or other health conditions, including heart failure, rather than inherited genetic mutations. Certain medications affect the heart's ability to electrically recover after each beat, prolonging the QT interval and increasing the risk of serious heart rhythm abnormalities. Acquired Long QT is not only drug-induced.
The prolonged-QT segment of HFrEF being studied in ASPIRE-HF is a form of acquired Long QT. Wave II focuses on congenital LQTS Types 2 and 3.
In the Wave I clinical study, SGK1 inhibition attenuated QTcF prolongation in a dofetilide-induced human model. Read the study abstract.
A healthcare professional can assess potential causes and guide care. Do not change prescribed medicines without medical advice
Two inherited types
LQT2 and LQT3
Our initial focus
LQT2
Caused by mutations in the KCNH2 gene that impair cardiac repolarization and prolong the QT interval.
LQT3
Driven by mutations in the SCN5A gene, resulting in an abnormal sodium channel current and QT prolongation.
Developing a disease-specific therapy for LQTS
Investigating SGK1 inhibition
Thryv is evaluating investigational THRV-1268 as a potential disease-modifying therapy in Long QT Syndrome. The research examines whether inhibiting SGK1 can shorten the QT interval and reduce the risk for arrhythmias.
THRV-1268 would be the first disease-modifying therapy in LQTS.
Now enrolling
Wave II: Long QT Syndrome Type 2 and Type 3
A Phase 2/3 study of THRV-1268 enrolling participants aged 15 and older with LQTS Type 2 or Type 3 and QTc >480 ms.
Patient community
The Foundation for Inherited Arrhythmias
The Foundation for Inherited Arrhythmias (FIA), formerly the SADS Foundation, is a nonprofit organization supporting individuals and families affected by inherited heart rhythm conditions, including Long QT Syndrome.
For more than 35 years, FIA has worked to improve care, accelerate cures and empower everyone affected by inherited arrhythmias to live fully and thrive beyond diagnosis. Its support spans guidance after a diagnosis, access to specialist care, peer support for families and partnerships that advance research.
Thryv is proud to work with FIA to help the Long QT Syndrome community find support, care guidance and information about studies. Learn more at fiacardiac.org.
The safety and efficacy of THRV-1268 have not been established. THRV-1268 is investigational; these research programs do not establish a treatment benefit. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g., the FDA in the United States, Health Canada in Canada, or the TGA in Australia).
If you are concerned about your health, please speak with your healthcare provider.